InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update
– Generated 38.8% growth in CGuard™ revenue year-over-year –
– Continued enrollment in the C-Guardian US IDE trial, with 24 sites currently enrolling patients; on track to complete enrollment by approximately end of Q1 2023 –
Related news for (NSPR)
- InspireMD Announces Combined Financings of $58 Million
- InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors
- 24/7 Market News Snapshot 31 July, 2025 – InspireMD, Inc. (NASDAQ:NSPR)
- 24/7 Market News Snapshot 31 July, 2025 – InspireMD, Inc. (NASDAQ:NSPR)
- 24/7 Market News Snapshot 24 June, 2025 – InspireMD, Inc. (NASDAQ:NSPR)